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a  b  s  t  r  a  c  t
The  German  Environmental  Specimen  Bank  (ESB)  continuously  collects  24-h  urine  samples  since  the
early  1980s  in Germany.  In this  study  we analyzed  300  urine  samples  from  the  years  2007  to 2015  for 21
phthalate  metabolites  (representing  exposure  to 11  parent  phthalates)  and  combined  the data  with  two
previous  retrospective  measurement  campaigns  (1988  to  2003  and  2002  to 2008).  The  combined  dataset
comprised  1162  24-h  urine  samples  spanning  the  years  1988  to 2015.  With  this  detailed  set of  human
biomonitoring  data  we describe  the  time  course  of phthalate  exposure  in Germany  over  a  time  frame  of
27 years.  For  the  metabolites  of  the  endocrine  disrupting  phthalates  di(2-ethylhexyl)  phthalate  (DEHP),
di-n-butyl  phthalate  (DnBP)  and  butylbenzyl  phthalate  (BBzP)  we  observed  a roughly  ten-fold  decline in
median  metabolite  levels  from  their  peak  levels  in  the  late 1980s/early  1990s  compared  to  most  recent
levels  from  2015.  Probably,  bans  (ﬁrst  enacted  in  1999)  and  classiﬁcations/labelings  (enacted  in  2001  and
2004)  in  the European  Union  lead to  this  drop.  A decline  in  di-isobutyl  phthalate  (DiBP)  metabolite  levels
set  in only  quite  recently,  possibly  due  to its later  classiﬁcation  as  a reproductive  toxicant  in  the  EU  in  2009.
In a  considerable  number  of  samples  collected  before  2002  health  based  guidance  values  (BE,  HBM  I) have
been exceeded  for DnBP  (27.2%)  and  DEHP  (2.3%)  but also  in recent  samples  some  individual  exceedances
can  still  be  observed  (DEHP  1.0%).  A decrease  in  concentration  for all  low  molecular  weight  phthalates,
labelled  or  not,  was  seen  in  the  most  recent  years  of  sampling.  For  the high  molecular  weight  phthalates,
DEHP  seems  to have  been  substituted  in  part  by  di-isononyl  phthalate  (DiNP),  but DiNP  metabolite  levels
have  also  been  declining  in  the  last  years.  Probably,  non-phthalate  alternatives  increasingly  take  over
for the  phthalates  in Germany.  A  comparison  with  NHANES  (National  Health  and  Nutrition  Examination
Survey)  data  from  the United  States  covering  the  years  1999  to 2012  revealed  both  similarities  and
differences  in phthalate  exposure  between  Germany  and  the  US.  Exposure  to  critical  phthalates  has
decreased  in  both  countries  with  metabolite  levels  more  and  more  aligning  with  each  other,  but  high
molecular  weight  phthalates  substituting  DEHP  (such  as DiNP)  seem  to  become  more  important  in  the
US than  in  Germany.
© 2016  Elsevier  GmbH.  All  rights  reserved.. Introduction
Phthalates are alkyl or aryl esters of phthalic acid (benzene-Please cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
,2-dicarboxylic acid). Depending on their alkyl chain length they
re mainly used as solvents and formulating agents (low molecu-
ar weight (LMW)  phthalates) or as plasticizers for polymers such
∗ Corresponding author.
E-mail address: koch@ipa-dguv.de (H.M. Koch).
ttp://dx.doi.org/10.1016/j.ijheh.2016.11.003
438-4639/© 2016 Elsevier GmbH. All rights reserved.as polyvinyl chloride (high molecular weight (HMW) phthalates)
(Koch and Calafat, 2009). Some phthalates have been identiﬁed as
endocrine disruptors in animal studies. Anti-androgenic properties
have been linked to the reduction of fetal testicular testosterone
production as one of the key events that lead to both structural
and functional impairment of male reproduction and developmentlites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
(Furr et al., 2014). The endocrine disrupting potency leading to
the multitude of effects termed the “phthalate syndrome” (Foster,
2006; Gray et al., 2006; National Research Council, 2008) seems to
be restricted to phthalates with a backbone chain length between
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hree and six carbon atoms and a total carbon count of the alkyl
hain between four (di-iso- and di-n-butyl phthalate, DiBP and
nBP) and nine carbon atoms (di-isononyl phthalate, DiNP). Based
pon the reduction of fetal testosterone production di-n-pentyl
hthalate (DnPeP) has been reported to be eightfold more potent
han di-(2-ethylhexyl) phthalate (DEHP) and the butyl phthalates
hile DiNP is threefold less potent (Furr et al., 2014; Hannas
t al., 2011a, 2011b; Lioy et al., 2015). Because endocrine disrupt-
ng effects observed in animal studies are judged as relevant for
umans, several phthalates have been classiﬁed as reproductive
oxicants in Europe over the last 15 years and use restrictions
nd bans have been enacted (see Supplementary Table 1). Gen-
rally, since February 2015 (REACH sunset date), phthalates listed
n Annex XIV of the REACH regulation (currently DiBP, DnBP, butyl
enzyl phthalate (BBzP) and DEHP) may  only be placed on the EU
arket or used in the EU if an authorization has been granted.
uch (temporary) authorizations for speciﬁc applicants and speci-
ed uses have been granted so far only for the use of DEHP during
he diffusion bonding and manufacture of aero engine fan blades
European Commission, 2014) or the use of DnBP as an absorption
olvent in a closed system in the manufacture of maleic anhydride
European Commission, 2016).
First human biomonitoring studies published at the turn of the
illennium revealed that the general population is ubiquitously
nd simultaneously exposed to several phthalates (Blount et al.,
000; Koch et al., 2003c). The number of urinary phthalate metabo-
ites used as biomarkers of exposure has increased ever since and
xposure to more than ten different phthalates can today be rou-
inely determined using a set of about 20 urinary metabolites
Frederiksen et al., 2014; Kasper-Sonnenberg et al., 2012, 2014;
och and Calafat, 2009; Silva et al., 2007). Phthalates are non-
ersistent chemicals, and the majority of a dose incorporated is
xcreted in urine within 24 h. Short chain, low molecular weight
hthalates such as dimethyl phthalate (DMP), diethyl phthalate
DEP), DiBP and DnBP are predominantly excreted in urine as
heir simple monoesters after ester cleavage. With increasing chain
engths oxidative modiﬁcation of the alkyl chain gains importance
nd high molecular weight phthalates such as DEHP, DiNP and di-
sodecyl phthalate (DiDP) are predominantly excreted as side chain
xidized monoester metabolites (Anderson et al., 2001; Barr et al.,
003; Koch et al., 2004, 2012a; Koch and Angerer, 2007; Koch and
alafat, 2009; Wittassek et al., 2011).
In Germany, urinary phthalate metabolite measurements have
een early on implemented in large scale population studies such as
he German Environmental Survey on children (GerES IV) (Becker
t al., 2004, 2009; Koch et al., 2007a; Schulz et al., 2012a; Wittassek
t al., 2007a) and in biobanked 24-h urine samples from the German
nvironmental Specimen Bank (ESB) (Kolossa-Gehring et al., 2012).
sing 24-h urine samples from ESB we already reported metabo-
ite levels of ﬁve phthalates in samples collected between 1988 and
003 (Wittassek et al., 2007b) and between 2002 and 2008 (Göen
t al., 2011). The ESB is a monitoring instrument of the Federal
inistry for the Environment, Nature Conservation, Building and
uclear Safety (BMUB), coordinated and maintained by the Ger-
an Environment Agency (UBA). One aim of the ESB is to document
nd assess exposure trends via human biomonitoring. In this study
e analyzed samples of the ESB collected between 2007 and 2015
xtending the spectrum to 21 metabolites representing exposure
o eleven phthalates. With the merged dataset we are now able to
escribe the time course of phthalate exposure over a time frame
f 27 years, spanning from early years (pre 2000) with no regula-
ory measures in place to the year 2015, the REACH sunset date forPlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
he phthalates DiBP, DnBP, BBzP, and DEHP. Based upon commonly
easured metabolites we are also able to compare our German ESB
4h-urine data with spot urine data from the US National Health PRESS
nd Environmental Health xxx (2016) xxx–xxx
and Nutrition Examination Survey (NHANES) covering the years
1999 to 2012.
2. Materials and methods
2.1. Subjects and urine specimens
For this study we analyzed phthalate metabolites in a subset
of urine samples from the German Environmental Specimen Bank
(ESB; www.umweltprobenbank.de). The ESB is a major component
of the German environmental observation system and provides a
scientiﬁc basis for decisions by the German Ministry for the Envi-
ronment (BMUB). The long-term storage of environmental and
human specimens is the main task of the ESB. Thus, these sam-
ples can be used to provide a continuous historical record of the
state of the environment in Germany, even if certain environmen-
tal toxicants were not in the scientiﬁc focus or analytical methods
did not exist at the time of collection. The ESB is coordinated and
administered by the German Environment Agency (UBA) which is
also responsible for scientiﬁc steering, central data maintenance
and data assessment. A unique feature of the ESB is that it continu-
ously collects 24-h urine samples in Germany since 1985 adhering
to strict standard operating procedures. The general concept and
sampling criteria of the ESB are described by Kolossa-Gehring et al.
(Kolossa-Gehring et al., 2012; Kolossa-Gehring, 2012; Schröter-
Kermani et al., 2016). All 24-h urine samples, after determination
of their full volume, are aliquoted into polypropylene tubes and
stored at temperatures below −150 ◦C (Lermen et al., 2014). The
study protocol of sampling human specimens has been reviewed
and approved by the ethics committees of the Medical Associa-
tions Saarland and Westfalen-Lippe and the Medical Faculty of the
Westphalian Wilhelms-University Münster. All participants gave
written informed consent on standardized forms approved by the
same ethics committees.
In this study, chemical analyses of phthalate metabolites was
performed in 300 urine samples collected in the years 2007, 2009,
2011, 2013 and 2015 (60 samples per year). All urine samples
were mainly from students (age range 20–29years) enrolled at the
University of Münster (Germany). For each year, volunteers were
evenly distributed between 30 males and 30 females. All urine
samples were blinded by the ESB before shipment to the ana-
lyzing laboratories at the IPA, Bochum, Germany. Samples were
stored at −20 ◦C prior to sample preparation and analysis. This
newly obtained dataset was then combined with the data from
two previous measurement campaigns covering the years 1988 to
2003 (Wittassek et al., 2007a,b) and the years 2002 to 2008 (Göen
et al., 2011). For harmonization, the age range of all datasets was
restricted to study participants aged 20–29 years (the core pop-
ulation of the ESB), which resulted in the elimination of 11 out
of the 240 participants from the second measurement campaign
(2002–2008) that also included individuals 19 and 30 years of age.
In all, phthalate HBM data from 1162 participants was included
in this analysis. Samples from all three measurement campaigns
have been collected at the same university in the city of Münster.
Detailed sample information and anthropometric data for all study
years are given in Table 1.
2.2. Chemical analysis
In the 24-h urine samples of the years 2007–2015 21 phtha-
late metabolites (representing exposure to 11 parent phthalates)lites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
were determined by on-line high performance liquid chromatog-
raphy coupled to tandem mass spectrometry (HPLC–MS/MS) using
internal isotope-labelled standards according to previously pub-
lished methods (Kasper-Sonnenberg et al., 2012; Koch et al.,
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Table  1
Anthropometric data of the study population (in bold: samples for ﬁrst time analyzed in this study).
Year Subject [number]
(male/female)
Age [years]
Mean (range)
24h-urine volume [mL]
(range)
Urinary creatinine [g/L]
(range)
1988 60
(30/30)
24.0
(21–29)
1520
(600–2800)
1.16
(0.20–2.23)
1989 60
(30/30)
24.1
(21–29)
1460
(500–2850
1.07
(0.49–2.79)
1991 60
(30/30)
24.5
(22–29)
1360
(400–2700)
1.30
(0.04–3.15)
1993 60
(30/30)
24.7
(20–29)
1660
(550–3100)
1.10
(0.26–2.63)
1996 146
(78/68)
24.2
(20–29)
1550
(290–2800)
1.11
(0.30–3.15)
1998 68
(38/30)
24.9
(20–29)
1570
(400–5000)
1.05
(0.22–2.57)
1999 60
(30/30)
24.0
(21–28)
1760
(700–4000)
1.01
(0.27–2.66)
2001 60
(30/30)
24.0
(20–29)
1750
(350–2800)
1.05
(0.30–2.43)
2002 57
(30/27)
23.0
(20–29)
1590
(650–2650)
1.13
(0.48–2.52)
2003 60
(30/30)
24.1
(20–28)
1750
(750–3650)
1.04
(0.28–2.95)
2004 60
(30/30)
24.2
(20–29)
1720
(460–3530)
1.11
(0.29–2.72)
2006 58
(29/29)
23.4
(20–28)
1980
(345–5030)
0.95
(0.29–2.52)
2007 60
(30/30)
24.2
(20–29)
1880
(930–3760)
0.89
(0.24–2.17)
2008 54
(29/25)
23.1
(20–29)
2140
(855–5460)
0.74
(0.15–1.73)
2009 60
(30/30)
23.1
(20–28)
1890
(540–3660)
0.83
(0.27–2.19)
2011 60
(30/30)
23.2
(20–29)
1820
(390–3050)
0.89
(0.25–2.20)
2013 60
(30/30)
23.7
(20–29)
1890
(500–3190)
0.79
(0.29–1.71)
2015 60
(30/30)
23.2
(20–29)
1940
(270–4600)
0.72
(0.15–2.20)
Total 1163 23.9
(20–29)
1730
(270–5460)
1.00
(0.15–3.15)
Female 569 23.5 1700 0.85
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Male 594 24.3
(20–29)
003b, 2007b, 2012a, 2012b; Preuss et al., 2005). The naming
f the parent phthalates and the respective monoester (primary
etabolites) and oxidized metabolites (secondary metabolites) is
hown in Table 2, including their limits of quantiﬁcation (LOQ). In
rief, for sample preparation, aliquots of 300 l of the urine sam-
les, calibration samples and quality control samples were added
o 100 l of ammonium acetate buffer (1 M;  pH = 6.0–6.4), 6 l
-Glucuronidase K12 from E.coli, arylsulfatase-free (Roche Diag-
ostics Mannheim, Germany; diluted 1:1 with ammonium acetate
uffer) and 10 l internal standard solution (of the isotope labelled
nalogues). Samples were incubated in a water bath for 2.5 h at
7 ◦C for enzymatic hydrolyses of the conjugates. After incubation,
0 l of acetic acid were added to samples to adjust the pH value.
amples were frozen for at least 3 h at −18 ◦C to precipitate pro-
eins. Thereafter, samples were thawed at room temperature and
entrifuged for 10 min  at 2,000g  and the supernatant was  trans-
erred into a 1.8 ml  glass vial for instrumental analysis.
For liquid chromatography 10 l of the above solution were
njected into an Agilent Technologies LC 1260 system (Agilent
260 autosampler, two Agilent 1260 binary pumps). Sample
lean-up and enrichment was performed on a Capcell Pak®C18-
G-II (10 × 4 mm,  particle size 5 m,  Phenomenex) column.Please cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
hromatographic separation was performed on an Atlantis dC18
2.1 × 150 mm;  3 m;  Waters). The solvents used were mixtures
f LC–MS grade water and acetic acid; 99.95:0.05 (solvent A) and(270–5460) (0.15–2.79)
1750
(490–5040)
1.15
(0.20–3.15)
mixtures of acetonitrile and acetic acid; 99.95:0.05 (solvent B). The
solvent gradients for the clean-up and analytical column are shown
in Supplementary Table 2a and b. The 6-port valve was switched at
7 min  to direct the analytical gradient in backﬂush mode through
the clean-up column onto the analytical column. At 28 min  the 6
port valve was  switched back into starting position. The total run
time for one sample was 34 min.
Mass spectrometric detection and quantiﬁcation was performed
on an AB Sciex 4500 triple quadrupole mass spectrometer used in
negative ionization mode (ESI-). For each analyte two ion transi-
tions were recorded. One was used for quantiﬁcation (quantiﬁer)
and the other one for veriﬁcation (qualiﬁer). For the labelled
internal standards one ion transition was  recorded. The mass spec-
trometer was operated in scheduled multiple reaction monitoring
(sMRM) mode. The respective ion transitions are given in Supple-
mentary Table 3. The precision of the method was determined
by analyzing a low and a high concentration control material
pooled from native urine samples in each analytical batch. Metabo-
lite concentrations and conjugation status thus represented the
characteristics of general population urine samples. Precision data
is presented in detail in Supplementary Table 4. Coefﬁcients of
variation were all below 16.1%. The accuracy of the method waslites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
determined by spiking standard solutions at two concentration
levels (20 g/L and 100 g/L) to native urine samples. Relative
recoveries for all metabolites were in the range between 86 and
ARTICLE IN PRESSG ModelIJHEH-13006; No. of Pages 12
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Table 2
Parent phthalates, metabolites and the respective Limits of Quantiﬁcation (LOQ).
Parent phthalate Primary
metabolite
Secondary
metabolite#
Full name of metabolite LOQ (g/L)
Low molecular weight
(LMW)  phthalates
Di-methyl phthalate (DMP) MMP  Mono-methyl phthalate 1.0
Diethyl phthalate (DEP) MEP  Mono-ethyl phthalate 0.5
Butylbenzyl phthalate (BBzP) MBzP Mono-benzyl phthalate 0.2
Di-isobutylphthalate(DiBP) MiBP Mono-isobutyl phthalate 1.0
2OH-MiBP 2OH-Mono-isobutylphthalate 0.25
Di-n-butyl phthalate (DnBP) MnBP Mono-n-butyl phthalate 1.0
3OH-MnBP 3OH-Mono-n-butyl phthalate 0.25
Di-cyclo-hexyl phthalate (DCHP) MCHP Mono-cyclo-hexyl phthalate 0.2
Di-n-pentylphthalate (DnPeP) MnPeP Mono-n-pentyl phthalate 0.2
High  molecular weight
(HMW)  phthalates
Di(2-ethylhexyl) phthalate
(DEHP)
MEHP Mono(2-ethylhexyl) phthalate 0.5
5OH-MEHP Mono(2-ethyl-5-hydroxy-hexyl) phthalate 0.2
5oxo-MEHP Mono(2-ethyl-5-oxo-hexyl) phthalate 0.2
5cx-MEPP Mono(2-ethyl-5-carboxy-pentyl) phthalate 0.2
Di-isononyl phthalate
(DiNP)
OH-MiNP 7-OH-(Mono-methyl-octyl) phthalate 0.2
oxo-MiNP 7-Oxo-(Mono-methyl-octyl) phthalate 0.2
cx-MiNP 7-Carboxy-(mono-methyl-heptyl) phthalate 0.2
Di-isodecyl phthalate (DiDP)and
Di-Propyl-heptyl phthalate (DPHP)*1
OH-MiDP 6-OH-Mono-propyl-heptyl phthalate 0.2
oxo-MiDP 6-Oxo-Mono-propyl-heptyl phthalate 0.2
cx-MiDP Mono(2,7-methyl-7-carboxy-heptyl) phthalate 0.2
Di-n-octyl phthalate (DnOP) MnOP Mono-n-octyl phthalate 0.2
MCPP*2 Mono-(3-carboxypropyl) phthalate 0.5
# differing metabolite abbreviations used in the US NHANES are as follows: 5OH-MEHP: MEHHP; 5oxo-MEHP: MEOHP; 5cx-MEPP: MECPP; cx-MiNP: MCOP; cx-MiDP: MCNP.
* bolite
* P, DnO
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(1  The analytical method applied cannot distinguish between DiDP and DPHP meta
2  Metabolite of several HMW  and LMW  phthalates (currently known: DnBP, DnPe
25%. The limits of quantiﬁcation (LOQ) of the individual phthalate
etabolites were derived based on a signal-to-noise ratio of 6 (see
able 1). Accuracy and international comparability of the analytical
rocedure was ensured and veriﬁed by the successful participation
n the External Quality Assessment Scheme (EQUAS) of the Euro-
ean COPHES/DEMOCOPHES projects on human-biomonitoring
Den Hond et al., 2015; Schindler et al., 2014) and by obtaining
ertiﬁcates of the German External Quality Assessment Scheme for
iological Monitoring (G-EQUAS, www.g-equas.de) offered for the
etabolites MnBP, MiBP, MBzP, MEHP, 5OH-MEHP, 5oxo-MEHP
nd 5cx-MEPP. The creatinine concentrations in urine were mea-
ured according to the Jaffé method.
.3. Statistical analysis
Calculations and statistical analysis was performed using
icrosoft® Excel 2010® and IBM® SPSS® Statistics 23. Descriptive
tatistical analyses (median, 95th percentile, range) were per-
ormed for metabolite concentrations expressed in g/L urine and
or creatinine adjusted concentrations in g/g creatinine. Con-
entrations below the respective LOQ were set to LOQ/2 for data
reatment. Box-plot visualization of the data was generated with
riginPro 9.1® from OriginLab Corporation.
. Results and discussion
.1. Phthalate metabolites in ESB (1988–2015)
Phthalate metabolite levels (in g/L) in the 24-h urine sam-
les of the ESB expressed as the median (50P), the 95th percentile
95P) and the maximum value are presented in Table 3a (metabo-
ites of the LMW  phthalates DMP, DEP, DiBP, DnBP and BBzP),
able 3b (metabolites of the HMW  phthalates DEHP and DiNP)
nd Table 3c (metabolites of the HMW  phthalates DiDP/DPHP and
nOP; and other metabolites: MCPP, MnPeP, MCHP). The tablesPlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
nclude the results from the two previous measurement campaigns
f 1988–2003 (Wittassek et al., 2007b) and 2002–2008 (Göen
t al., 2011). The results of the current measurement campaign
2007–2015) are highlighted in bold. Results after creatinine cor-s.
P, DiNP, DiDP). MCPP has also been abbreviated in previous studies with 3cx-MPP.
rection (in g/g creatinine) are reported in analogous fashion in
the Supplementary Tables 5a–c. The metabolites MMP, MEP, 2OH-
MiBP, 3OH-MnBP, OH-MiDP, oxo-MiDP, cx-MiDP, MnOP, MCPP,
MnPeP and MCHP are for the ﬁrst time reported in the current mea-
surement campaign. Cx-MiNP has been included since the second
campaign (2002–2008). The results from the current measurement
campaign are in line with the results of the previous campaigns. All
metabolites except MnPeP, MCHP and MnOP could be detected and
quantiﬁed in the vast majority of samples analyzed. For MnPeP,
MCHP and MnOP we  recorded only sporadic detections at very
low levels. Box-plots of the urinary concentrations (in g/L) for the
individual metabolites over the years investigated are depicted in
Supplementary Figs. 1a–c. For those phthalates captured via more
than one metabolite (DiBP, DnBP, DEHP, DiNP, DiDP) we observed
strong correlations between the respective metabolites over the
whole concentration range (data not shown), conﬁrming the ﬁnd-
ings of various previous studies (Barr et al., 2003; Becker et al., 2004;
Enke et al., 2013; Göen et al., 2011; Koch et al., 2003c, 2012b).
For the low molecular weight phthalates, the simple monoesters
are the major urinary metabolites, while for the high molecular
weight phthalates side chain oxidized monoester metabolites are
the major urinary metabolites. Because urinary excretion fractions
differ in part considerably between the various phthalates and their
metabolites, a direct comparison between urinary metabolite levels
in terms of exposure to the respective parent phthalates is difﬁ-
cult. E.g. similar urinary metabolite levels of the simple monoesters
MnBP and MEHP indicate to external DEHP exposures that are
roughly 10-times higher than external DnBP exposure. Such expo-
sure extrapolations need to take into account urinary metabolite
conversion factors, daily urine volume and other anthropomet-
ric factors (David, 2000; Koch et al., 2003a; Kohn et al., 2000;
Wittassek et al., 2007b) and will be performed in a sister publica-
tion (in preparation). However, with this caveat in mind, the urinary
metabolite levels can be used to investigate the general time course
of phthalate exposure over the years preserved in the ESB samples,
to investigate for possible differences between the males and thelites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
females of the ESB population, to compare metabolite levels with
biomarker derived health-based guidance values (such as the BE,
biomonitoring equivalent; HBM I, human biomonitoring value I)
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Table  3
(a) Urinary metabolite levels (in g/L) of the low molecular weight phthalates DMP, DEP, DiBP, DnBP and BBzP.
DMP  DEP DiBP DnBP BBzP
MMP  MEP  MiBP 2OH-MiBP MnBP 3OH-MnBP MBzP
50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max
1988 – – – – – – 29.3 108 318 – – – 178 724 882 – – – 7.8 22.8 203
1989  – – – – – – 27.7 104 187 – – – 189 578 1480 – – – 8.7 35.6 79.1
1991  – – – – – – 39.8 390 588 – – – 182 429 699 – – – 15.4 69.5 99.7
1993  – – – – – – 29.8 89.1 209 – – – 164 1090 1970 – – – 7.2 48.0 86.0
1996  – – – – – – 42.9 235 534 – – – 105 443 2090 – – – 8.4 126 687
1998  – – – – – – 36.5 207 263 – – – 79.2 293 686 – – – 7.5 38.5 95.5
1999  – – – – – – 32.1 133 216 – – – 71.7 362 800 – – – 5.2 87.2 289
2001  – – – – – – 32.7 161 435 – – – 63.4 443 1780 – – – 5.2 23.8 39.8
2002  – – – – – – 30.7 96.1 172 – – – 66.4 155 7490 – – – 8.0 30.1 58.0
2003  – – – – – – 30.4 107 151 – – – 50.8 131 704 – – – 5.9 18.9 30.6
2004  – – – – – – 25.4 64.6 100 – – – 38.5 101 2370 – – – 6.3 17.0 186
2006  – – – – – – 31.8 142 317 – – – 29.3 105 250 – – – 3.6 15.6 31.8
2007  8.0 102 147 53.6 400 1910 19.3 79.3 121 8.2 24.0 39.7 16.4 37.3 57.0 1.4 4.1 5.4 2.9 16.9 44.0
2008  – – – – – – 24.5 98.1 231 – – – 19.4 63.8 73.1 – – – 3.8 10.1 21.6
2009  7.1 54.6 182 37.5 317 1160 19.7 79.4 132 5.9 27.3 60.5 16.3 48.9 72.6 1.4 3.7 7.6 3.2 16.0 37.7
2011  4.4 35.2 40.3 17.9 190 6080 20.3 50.8 133 5.8 22.0 36.5 14.8 27.3 43.3 1.5 4.0 5.8 3.3 13.2 66.5
2013  3.5 29.2 58.0 20.9 93.3 502 16.4 52.5 52.9 4.6 12.3 21.4 11.2 29.9 93.2 1.1 3.0 7.6 2.0 12.8 27.6
2015  2.8 14.3 22.1 13.5 71.2 468 9.8 33.4 670 2.8 11.9 203 8.0 21.3 42.0 0.8 2.9 4.7 1.2 13.7 134
(b)  Urinary metabolite levels (in g/L) of the high molecular weight phthalates DEHP and DiNP.
DEHP DiNP
MEHP 5OH-MEHP 5oxo-MEHP 5cx-MEPP OH-MiNP oxo-MiNP cx-MiNP
50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max
1988 9.4 30.0 94.5 27.8 77.8 275 20.1 62.3 251 27.8 84.5 340 1.5 7.3 11.4 0.6 3.3 4.3 – – –
1989  9.7 32.1 129 28.2 60.8 275 22.0 46.2 196 39.0 75.0 282 1.8 13.7 53.4 0.7 3.6 32.5 – – –
1991  10.4 39.8 62.4 36.0 114.0 142 25.6 80.3 118 40.2 142.5 241 2.2 12.8 85.4 0.8 3.1 38.4 – – –
1993  8.4 34.4 88.0 26.0 85.5 133 20.1 62.2 109 30.3 108.3 159 1.8 10.0 12.3 0.7 4.8 9.0 – – –
1996  7.8 31.6 68.8 20.0 80.6 216 16.1 57.2 192 26.8 116.1 300 2.0 10.9 27.9 1.0 5.0 15.2 – – –
1998  6.7 29.6 64.3 17.0 56.2 165 14.3 44.8 181 21.6 70.5 181 2.1 37.0 59.3 1.1 24.2 50.6 – – –
1999  5.4 18.8 36.8 13.4 52.1 77.7 11.1 33.1 67.8 18.7 57.7 167 1.9 10.9 17.9 1.0 7.2 11.5 – – –
2001  6.4 29.3 48.0 16.4 59.1 113 14.0 43.0 109 23.0 69.2 185 2.1 13.6 57.7 1.1 5.3 63.8 – – –
2002  7.2 18.7 41.9 19.7 51.8 63.8 14.0 34.3 50.3 19.0 50.6 59.1 3.5 9.8 35.9 2.2 6.2 15.7 4.3 10.8 40.6
2003  4.6 23.2 63.9 13.4 37.6 83.2 12.2 34.3 57.9 17.5 54.5 129 2.3 9.8 29.0 1.6 5.9 19.1 – – –
2004  5.6 32.5 63.5 16.2 102.7 134 11.8 59.8 108 16.5 87.4 135 2.8 16.0 63.9 2.1 9.5 37.9 3.2 12.4 63.4
2006  4.1 11.1 16.2 13.2 29.4 38.9 8.3 25.2 33.1 13.5 30.7 36.7 3.2 20.2 24.7 2.2 14.4 24.9 4.0 28.2 40.4
2007  3.6 23.0 58.0 10.8 41.5 192 6.3 22.0 106 12.7 46.6 270 2.2 10.4 30.4 1.0 4.4 10.2 2.0 8.0 19.2
2008  3.3 12.3 15.9 9.3 22.3 28.5 5.9 14.1 15.3 9.7 23.6 26.1 3.6 17.6 35.9 2.2 12.6 27.2 3.5 25.1 41.8
2009  3.4 10.8 33.1 8.8 34.8 244 5.1 17.5 101 8.9 38.8 121 2.4 12.2 39.1 1.2 7.9 21.0 2.8 11.9 73.3
2011  1.8 4.8 8.3 7.5 18.3 28.3 5.6 13.9 24.1 7.3 20.1 34.0 2.9 23.2 212 1.7 14.3 156 3.7 20.3 158
2013  1.4 4.4 9.7 5.7 14.8 21.5 3.9 11.4 17.1 5.9 14.8 20.9 2.5 8.2 38.7 1.1 4.0 26.6 2.3 9.6 44.0
2015  1.1 4.4 14.6 4.2 17.9 62.9 3.2 10.7 41.1 3.8 14.0 49.9 2.4 15.3 23.3 0.9 4.7 18.4 2.0 12.5 57.0
(c)  Urinary metabolite levels (in g/L) of the high molecular weight phthalates DiDP/DPHP and DnOP; and other metabolites (MCPP, MnPeP, MCHP) for the ﬁrst time reported in samples of the ESM hum.
DiDP/DPHP DnOP various DnPeP DCHP
OH-MiDP oxo-MiDP cx-MiDP MnOP MCPP MnPeP MCHP
50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max  50P 95P Max
2007 0.7 3.9 23.3 0.3 1.7 12.9 0.5 3.2 13.0 <LOQ <LOQ 1.0 0.6 3.5 7.8 <LOQ <LOQ 0.2 <LOQ <LOQ 0.2
2009  0.7 2.4 18.3 0.3 1.1 4.1 0.5 1.5 12.9 <LOQ <LOQ <LOQ 0.6 2.2 5.6 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
<LOQ
<LOQ
<LOQ
a
u
o
3
r
H
s
E
m2011  1.0 5.9 47.7 0.2 1.5 10.5 0.6 2.7 24.1 <LOQ 
2013  0.8 3.0 9.3 0.3 1.6 12.9 0.4 1.1 4.0 <LOQ 
2015  0.8 3.4 5.2 0.3 0.8 2.1 0.4 1.5 5.1 <LOQ 
nd to compare metabolite levels from this study with other pop-
lation studies such as NHANES that also provide metabolite data
ver a longer time frame (1999–2012).
.2. Time course of metabolite excretion in ESB (1988–2015)
In Fig. 1 we present the median urinary levels of major or rep-
esentative metabolites of the LMW  phthalates (Fig. 1A) and thePlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
MW phthalates (Fig. 1B) for each year included in the three mea-
urement campaigns of ESB. In earlier measurements from the
SB, MnBP (the major metabolite of DnBP) has been the dominant
etabolite in the full spectrum of phthalate metabolites. Median <LOQ 0.7 2.8 22.5 <LOQ <LOQ <LOQ <LOQ <LOQ 0.4
 0.7 0.5 1.9 20.0 <LOQ <LOQ 1.3 <LOQ <LOQ 1.2
 <LOQ 0.3 2.9 23.3 <LOQ <LOQ 0.7 <LOQ <LOQ 0.9
levels were higher than 100 g/L in the late 1980s and early 1990s
but decreased to levels below 10 g/L in 2015. This decrease in
exposure seems to have been inﬂuenced by the provisional ban
of DnBP in toys and childcare articles commencing in 1999 which
was made permanent by an EU Directive in 2005 (2005/84/EC).
Another decision considerably inﬂuencing the decrease in DnBP
exposure seems to have been its classiﬁcation as a reproductive
toxicant in 2001 (see Supplementary Table 1) which also prohibitedlites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
its use in cosmetics. The structural analogue of DnBP, the phthalate
DiBP has not been prohibited for use in toys and childcare arti-
cles but has been shown to have a toxicological proﬁle similar to
DnBP in the meantime (Furr et al., 2014; Hannas et al., 2011b). Ini-
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Fig. 1. Concentrations of key LMW  and HMW phthalate metabo
ially, MiBP levels have been lower than MnBP levels, but contrary
o MnBP MiBP metabolite levels remained rather constant until
011 (between 20 and 40 g/L), surpassing the metabolite levels of
nBP in 2006. In the last years, probably due to its classiﬁcation as
 reproductive toxicant in 2009, also for MiBP a decline in metabo-
ite levels set in to median levels around 10 g/L in 2015. For MBzP,
etabolite levels have always been lowest in the metabolite spec-
rum of LMW phthalate metabolites. Metabolite levels dropped
rom values around 10 g/L in the early 1990s to a median value
f around 1 g/L in 2015, paralleling the decline in MnBP levels.
imilar to DnBP, BBzP has been banned in toys and childcare arti-
les since 1999 and labelled as a reproductive toxicant in 2004. The
etabolites MMP  and MEP  have only been included in the latest
easurement campaign. The parent phthalates DMP  and DEP are
ot restricted in Europe. However, also for these phthalates a con-
iderable decline in metabolite levels (for MMP  from around 8 g/L
n 2007 to 3 g/L in 2015; for MEP  from 54 g/L in 2007 to 14 g/L
n 2015) is apparent, possibly due to the increasing demand for
phthalate-free” cosmetics.
The time course of metabolite excretion for the HMW  phtha-
ates DEHP, DiNP and DiDP/DPHP is illustrated in Fig. 1B by their
ydroxylated metabolites 5OH-MEHP, OH-MiNP and OH-MiDP,
espectively. For 5OH-MEHP, similar to the restricted/classiﬁed
MW phthalates, there is an apparent decline from median metabo-
ite levels around 30 g/L in the early 1990s to around 4 g/L in
015. DiNP (and DiDP) have been restricted in certain toys since
999 but have not been labelled as reproductive toxicants. How-
ver, DiNP has been shown to possess some endocrine disrupting
otential, around a factor of 3 weaker than DEHP (Furr et al., 2014;
annas et al., 2011b). For the DiNP metabolite OH-MiNP some
ncrease from 1.5 g/L in 1988 to values above 3 g/L between
002 and 2008 seems to have turned to lower median values again
2.4 g/L in 2015). OH-MiDP median values have only been ana-
yzed in the latest measurement campaign, but are below 1 g/L.
H-MiDP reﬂects exposure to DiDP and DPHP, because the applied
PLC method cannot distinguish between the speciﬁc metabolitesPlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
f DPHP and the isomeric metabolite mixture of DiDP (Gries et al.,
012). Schütze et al. (2015) have recently shown, based upon sam-
les from the ESB, that the DPHP speciﬁc metabolite OH-MPHP only
ontributes a negligible share to the isomeric OH-MiDP metabo-Sampling Year
median, in g/L) in the German ESB over the years 1988–2015.
lite (Schütze et al., 2015). However, the same authors have also
reported that the ESB samples indicate an increasing exposure to
DPHP.
3.3. Male vs. female metabolite levels in ESB (2007–2015)
In Table 4 the median metabolite levels of the male and female
subpopulation are depicted for the individual years of the recent
measurement campaign and the recent measurement campaign
as a whole (in bold). With some ﬂuctuations between the years,
viewed over all years, median values for males and females are
remarkably similar and do not indicate to profound exposure
differences between males and females. This is in general agree-
ment with the previous ESB measurement campaigns. For the
DEHP metabolites 5OH-MEHP and 5oxo-MEHP Göen et al. (2011)
reported somewhat higher 5OH-MEHP levels and somewhat lower
5oxo-MEHP levels in males compared to the females, which is also
conﬁrmed in the present study. This observation might point to
some gender dependent difference in oxidative DEHP metabolism.
Other studies, including studies from our group, have reported
some exposure driven differences in phthalate levels between male
and female populations and depending upon age and other factors,
most probably caused by different lifestyle and nutritional pattern.
These inﬂuencing factors are probably not captured by the rather
homogeneous composition of our study population (young, healthy
adults, 20–29 years). Therefore, we  consider the ESB study popula-
tion as a reliable source providing general time trends of phthalate
exposure. However, speciﬁc sub-populations such as children or
pregnant women  might experience phthalate exposures that are
higher (or lower) than reported for the ESB population.
3.4. Metabolite levels compared to biomarker derived
health-based guidance values
The urinary metabolite levels determined in the 24 h urine sam-lites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
ples of the ESB can be compared to health based guidance values
(see Table 5). Such health based guidance values, called biomoni-
toring equivalents, BE, (Hays et al., 2007; Hays and Aylward, 2012)
or human biomonitoring values, HBM values, from the German
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Table  4
Median metabolite levels (in g/L) of the male (♂) and female (♀) population of the German ESB over the sampling years 2007–2015.
2007 2009 2011 2013 2015 2007–2015
♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀
n 30 30 30 30 30 30 30 30 30 30 150 150
MMP  5.1 8.0 8.0 6.4 4.3 4.5 3.3 3.6 3.0 2.5 4.2 4.5
MEP  91.5 34.0 27.2 51.6 23.1 16.4 18.0 23.2 14.1 12.3 23.9 23.8
MiBP  23.1 16.7 21.7 19.0 17.4 26.1 17.0 13.7 10.0 9.1 17.1 15.5
2OH-MiBP 8.2 7.6 6.2 5.9 4.5 7.8 4.8 4.4 2.9 2.6 4.7 5.2
MnBP  18.8 14.8 13.9 17.4 11.0 20.5 10.5 11.6 8.0 7.8 11.1 12.5
3OH-MnBP 1.4 1.5 1.4 1.4 1.1 1.8 1.1 1.1 0.8 0.8 1.3 1.2
MBzP  3.6 2.6 3.0 3.3 2.6 3.9 2.2 1.9 1.5 1.1 2.6 2.5
MEHP  4.5 3.5 3.2 3.4 1.9 1.7 1.5 1.3 1.2 1.0 2.3 2.0
5OH-MEHP 11.6 10.4 8.5 9.2 6.9 8.9 6.2 5.0 4.5 4.2 7.4 6.8
5oxo-MEHP 6.2 6.3 4.6 5.6 4.7 6.5 3.7 4.7 2.8 3.3 4.5 4.9
5cx-MEPP 11.7 13.0 8.4 9.2 6.8 9.1 5.8 6.3 3.6 4.0 6.9 7.3
7OH-MiNP 2.5 1.5 2.5 2.4 2.3 3.1 2.2 2.8 2.6 2.3 2.5 2.4
7oxo-MiNP 1.1 0.9 1.2 1.2 1.4 2.0 1.2 1.1 0.8 1.0 1.2 1.2
7cx-MINP 2.2 1.6 2.8 2.9 3.6 3.9 2.0 2.5 2.3 1.9 2.5 2.4
OH-MiDP 0.9 0.7 0.8 0.7 1.0 0.9 0.9 0.6 0.6 0.8 0.8 0.7
oxo-MiDP 0.4 0.3 0.3 0.3 <LOQ 0.2 0.2 0.2 <LOQ 0.4 0.3 0.3
cx-MiDP 0.6 0.5 0.6 0.5 0.6 0.6 0.4 0.3 0.4 0.4 0.5 0.5
MCPP  0.7 0.6 0.6 0.7 0.6 0.8 <LOQ 0.5 <LOQ <LOQ 0.6 0.6
Table 5
German ESB participants exceeding health based guidance values derived for urinary phthalate metabolites.
Phthalate health-based guidance value % exceeding health based guidance value
Type # Biomarkers/metabolites Value ESB total
(1985–2015)
ESB pre 2002
(1985–2001)
ESB
(2007–2015)
DEP BE MEP  18,000 g/L 0 0 0
BBzP  BE MBzP 3800 g/L 0 0 0
DnBP  BE MnBP 200 g/L 13.8 27.2 0
DEHP  HBM-I value 5OH-MEHP + 5oxo-MEHP 300 g/L (women in childbearing age) 0.5 1.1 0
5OH-MEHP + 5oxo-MEHP 750 g/L (adult males) 0 0 0
BE  MEHP + 5OH-MEHP + 5oxo-MEHP 260 g/L 1.5 2.3 1.0
DiNP  BE OH-MiNP + oxo-MiNP + cx-MiNP 1800 g/L 0 0 0
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Mbbreviations: HBM-I value: human biomonitoring value I, BE: biomonitoring equi
 health based guidance values for DEP, BBzP, DnBP: Aylward et al., 2009a; DEHP: S
uman Biomonitoring Commission (Angerer et al., 2011; Schulz
t al., 2012b) have been derived for several phthalates.
The derivation of these BE and HBM values has been based on
elating a chronic exposure guidance value (such as the TDI, ADI or
he RfD) to steady-state concentrations of phthalate metabolites
n urine. While phthalate exposure is known to occur intermit-
ently (Preau et al., 2010), and due to rapid elimination kinetics
Wittassek et al., 2011), urinary metabolite concentrations can vary
ubstantially in spot urine samples. The 24 h urine samples of the
SB represent a good approximation of the mean (chronic) expo-
ure over a period of one day. Thus, contrary to spot urine samples,
here interpretation has to be performed with added caution in
espect to BE or HBM values, we consider the 24 h urine samples
f the ESB a highly robust measure of the mean daily exposure,
ven at the upper percentiles or maximum metabolite concentra-
ions of the study population. Previous studies have shown that
he mean (or median) concentrations of biomarkers determined
n population studies from spot urine samples or 24 h urine sam-
les are very comparable. However, high-end concentrations (95th
ercentiles and maxima) in a population of 24-h samples tend to
e only half the high-end concentrations in a population of spot
amples (Aylward et al., 2016; Christensen et al., 2012).
The BE guidance values for DEP, BBzP and DiNP have never beenPlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
xceeded in any of the ESB samples. The maximum value observed
or MEP  (6080 g/L) in 2011 is a factor of three below the respec-
ive BE value of 18,000 g/L; the maximum value observed for
BzP (687 g/L) in 1996 is a factor of ﬁve below the respective.
 et al., 2012a,b and Aylward et al., 2009b; DiNP: Hays et al., 2011.
BE value of 3800 g/L (Aylward et al., 2009b). DiNP metabolite lev-
els were several orders of magnitude below the BE value. This BE
value has been derived from the EFSA TDI (Spongiosis hepatitis)
and does not take account of the endocrine disrupting potency of
DiNP (Hays et al., 2011). For the DnBP metabolite MnBP around
14% of all ESB samples from 1988 to 2015 exceeded the BE value
of 200 g/L. However, these exceedances mainly occurred in urine
samples collected before 2002. 27% of these samples from 1988
to 2001 exceeded the BE value. In none of the samples from the
recent measurement campaign (2007–2015) the BE value has been
exceeded. In 2015, the 95th percentile of urinary MnBP (21.3 g/L,
see Table 3a) has been a factor of 10 lower than the BE. Consid-
ering a similar toxicological proﬁle of DiBP, but with no BE value
derived so far, the 95th percentile of urinary MiBP (33.4 g/L, see
Table 3a) has also been considerably below the BE derived for MnBP.
For the DEHP metabolites both HBM values and BE values have been
derived, based on a slightly different set of metabolites, and based
upon different toxicological endpoints (Aylward et al., 2009a; HBM
Commission, 2007; Schulz et al., 2012b). In the ESB samples col-
lected before 2002 2.3% of the study population exceeded the BE
value and 1.1% of the women  exceeded the HBM I value. While no
exceedances of the HBM I value were observed for the samples
from the recent measurement campaign (2007–2015), still 1.0%lites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
exceeded the BE value.
Currently, HBM and BE values do only evaluate exposures to sin-
gle phthalates. Endocrine active phthalates, however, are known
to act in a concerted, dose additive manner (Howdeshell et al.,
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008b, 2008a, 2015; Lioy et al., 2015; National Research Council,
008). As can be seen from this and other studies, the population
s still continuously and simultaneously exposed to a wide range
f different phthalates. A cumulative risk assessment based upon
etabolite levels in the ESB, taking into account their common anti-
ndrogenic potential, will therefore be performed in a subsequent
tudy (publication in preparation).
.5. Metabolite levels from ESB (1988–2015) compared to
HANES (1999–2012, 20 years and older)
We  can compare metabolite levels and time courses of excre-
ion of the metabolites over the years investigated in the German
SB with metabolite data published in the exposure reports of U.S.
HANES. Temporal trends for phthalate exposure in the US have
lready been reported by Zota et al. (Zota et al., 2014) encompass-
ng NHANES data from 2001 to 2010. In the most recent exposure
eport (Fourth report, Updated Tables, February 2015, www.cdc.
ov/exposurereport/; last accessed July 20, 2016) nationally rep-
esentative biomonitoring data (for the non-institutionalized U.S.
opulation) have been published for the phthalates starting from
he sampling years 1999/2000 in 2-year intervals with the most
ecent set from 2011/2012. Contrary to the 24 h urine samples of
SB, NHANES is based on spot urine samples with sampling ses-
ions in the morning, the afternoon, or the evening. For comparison
ith ESB we selected the reported median levels (in g/L) of the
HANES population subset “20 years and older”. The sample size of
his subset ranged between 1461 and 1914 for each of the two-year
HANES cycles with a total sample size of 11,565.
In Fig. 2, concentrations of key metabolites (median, in g/L)
f eight phthalates (DMP, DEP, BBzP, DiBP, DnBP, DEHP, DiNP and
iDP) determined in both populations are depicted, separately for
he respective study years. MCPP, a metabolite of several LMW
nd HMW  phthalates, cannot be attributed to a single phthalate.
n ﬁrst sight one can see similarities and differences between
SB and NHANES, both in terms of urinary metabolite levels and
ime courses over the years investigated. As a common feature,
he worldwide change in the phthalate market, with dramatic
hanges in phthalate production and uses, inﬂuenced by toxico-
ogical ﬁndings and national regulations and restrictions, seems to
e reﬂected in the biomonitoring data (Bizzari et al., 2013; Lioy
t al., 2014). However, also country speciﬁc production and use
atterns seem to exist. For the LMW  phthalate DMP, MMP  metabo-
ite levels indicate considerably lower exposures in the US (median
evels for 2003/2004 and 2005/2006 were below the LOQ) com-
ared to Germany. German levels, however decreased from 8 g/L
in 2007) to 2.8 g/L (in 2015). For DEP, MEP  levels in the US
teeply declined from 125 g/L in 2003/2004 to around 30 g/L
n 2011/2012. German values were generally lower, also declin-
ng, but settling at concentrations around 20 g/L. MBzP levels
eemed to decline in both countries with only slightly higher lev-
ls in the US (metabolite levels in both countries in 2011/2012
round 4 g/L). For the butyl phthalate isomers DiBP and DnBP
ome counter-rotating developments can be observed for MiBP.
hile MiBP levels were considerably higher for many years in
ermany (around 30 g/L until 2006), US levels were very low
n 2001/2002 (2.4 g/L) but tripled to levels around 7.5 g/L in
009/2010. In both countries, in recent years, levels seem to be
eclining. Historically, DnBP exposures seem to have been much
igher in Germany (median values peaking almost 200 g/L in the
arly 1990s) compared to the US, albeit the ﬁrst direct compari-Please cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
on is only possible for the years 1999/2000 (Germany: 72 g/L;
S: 23 g/L). Due to the rapid decline in Germany with stable val-
es in the US until 2007/2008, recent metabolite levels are quite
omparable (10–15 g/L). PRESS
nd Environmental Health xxx (2016) xxx–xxx
Based upon the carboxylated metabolites of the HMW  phtha-
lates DEHP, DiNP and DiDP (measured both in NHANES and
ESB) again similarities and differences can be observed between
Germany and the US. DEHP exposure has been dropping in both
countries with cx-MEPP concentrations in the US  always slightly
higher than in Germany. However, historic German levels from
the early 1990s were higher than US levels from 2001/2002. For
DiNP, metabolite data is indicating to considerably different devel-
opments in Germany and the US. While metabolite levels have been
rather comparable in 2005/2006 (around 4 g/L) metabolite lev-
els have been steeply increasing in the US to almost 20 g/L in
2011/2012 with German levels constantly remaining below 4 g/L,
even dropping to 2 g/L in 2015. For DiDP, no time trends are
apparent for the US and Germany, but US metabolite levels are
5-times higher (2.5 g/L vs. 0.5 g/L). The somewhat higher expo-
sure to HMW  phthalates in the US (especially DiDP) might also be
reﬂected in the 5-times higher levels of MCPP. In this respect, it has
again to be pointed out, that ESB samples are collected as complete
24 h urine samples while NHANES samples are collected as spot
urine samples. While there are indications that population data
based on spot urine samples results in somewhat higher concentra-
tions in the upper percentiles than population data based on 24 h
urine samples, population means and population medians result-
ing from the two sampling regimes are very comparable (Aylward
et al., 2016; Christensen et al., 2012). A more detailed compari-
son between NHANES and ESB data (not shown) indeed reveals
that at comparable median concentrations, the 95th percentiles in
NHANES are two- to three-times higher than in the ESB. In part,
this observation can certainly be attributed to the different sam-
pling regimes (spot vs. 24 h). Other reasons for the larger spread in
NHANES compared to ESB might be that the study population in
NHANES is much more heterogeneous in terms of age, ethnicity,
geography, social background, lifestyle etc. than the rather homo-
geneous study population of the ESB at one sampling location.
4. Conclusions
With this study we provide valuable insights into the time
course of phthalate exposure in Germany from 1988 to 2015.
Exposure to most critical (endocrine active) phthalates has been
considerably higher before the turn of the millennium but var-
ious regulatory measures enacted in Europe and changes in the
phthalate market obviously have led to a decline in exposures.
For phthalates regulated at a later stage (such as DiBP) also their
decline set in at later years. In recent years, exposure to most of
the phthalates, regulated or not (such as DMP  and DEP), seems
to be declining, probably because of a dwindling acceptance of
phthalate-containing products and the rising importance of phtha-
late alternatives. For those phthalates used as plasticizers for
polymers, the drop in DEHP exposure has only resulted in a mod-
erate increase in exposure to DiNP, a possible substitute with no
labelling requirements. In Germany, DEHP does not seem to be fully
substituted by other HMW  phthalates (e.g. DiNP and DiDP), but
also by non-phthalate, non-aromatic plasticizers. We  have previ-
ously reported, also based upon ESB samples, a profound increase in
exposure to DINCH (1,2-Cyclohexane dicarboxylic acid diisononyl
ester) (Schütze et al., 2012, 2014). In a pilot study we have also
reported the widespread exposure to di-(2-ethylhexyl) terephtha-
late (DEHTP) in Germany (Lessmann et al., 2016a, 2016b). Currently,
we assume these alternatives having a preferred toxicological
proﬁle over the regulated phthalates. Nevertheless, a continuouslites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
surveillance of these alternatives is advisable as it allows interven-
ing with regulatory measures, if exposures are exceeding health
benchmarks, or if new toxicological ﬁndings lead to a re-evaluation
of these health benchmarks.
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f  sampling (black diamonds for ESB, white boxes for NHANES).
A comparison with health based guidance values for individual
hthalates showed, that ESB participants exceeded health bench-
ark values (BE, HBM I) for DEHP and DnBP mainly in the years
efore regulations set in. Still, 1% of the study population exceededPlease cite this article in press as: Koch, H.M., et al., Phthalate metabo
imen Bank (ESB) from 1988 to 2015 and a comparison with US NHA
http://dx.doi.org/10.1016/j.ijheh.2016.11.003
he BE of DEHP also in the most recent measurement campaign. Two
spects have to be kept in mind in regard to these ﬁndings: ﬁrst,
ndocrine active phthalates are known to act in a dose additive
anner, and, albeit exposures to individual phthalates are below20–29 years) compared to US NHANES (20 years and older) over the different years
respective health based guidance values, the cumulative phthalate
exposure might still exceed levels indicating concern (Lioy et al.,
2015; National Research Council, 2008). Second, the study popu-
lation of the ESB cannot be regarded representative for the wholelites in 24-h urine samples of the German Environmental Spec-
NES data from 1999 to 2012. Int. J. Hyg. Environ. Health (2016),
German population. Data from the German Environmental Survey
(GerES) indicates that children can experience higher exposures
to some phthalates than adults and younger children have higher
exposures than older children or adolescents (Koch et al., 2007a;
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ittassek et al., 2007a). Similarly, other sub-populations with spe-
iﬁc food consumptions or life-style habits might also experience
ifferent (or higher) amplitudes of phthalate exposure.
A comparison of ESB with NHANES has shown that phtha-
ate exposures in general are rapidly changing with similarities
etween countries but also country speciﬁc differences. A compari-
on of worldwide human biomonitoring data of phthalate exposure
herefore has always to take into account the country of origin and
he year the respective samples are collected. Even within Europe
e can ﬁnd in part considerable differences in phthalate exposure
Cerna et al., 2015; Den Hond et al., 2015). Although regulatory
easures on phthalates are the same within the European Union,
ountry speciﬁc characteristics in life-style, product use and/or
ood consumption can lead to differences in phthalate exposure.
The results from this study illustrate that human biomonitor-
ng is an ideal tool to describe and evaluate phthalate exposure
oth in the past (documenting the effect and success of regulatory
easures on the exposure) but also in regard to recently col-
ected samples (documenting the current extent of exposure). Thus,
uman biomonitoring is able to profoundly support and comple-
ent the whole process in a chemical’s evaluation from exposure
ssessment, via risk assessment to risk management.
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